Edition:
United Kingdom

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

1.62USD
22 May 2019
Change (% chg)

$0.02 (+1.25%)
Prev Close
$1.60
Open
$1.60
Day's High
$1.64
Day's Low
$1.59
Volume
25,919
Avg. Vol
64,034
52-wk High
$5.10
52-wk Low
$1.50

About

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's... (more)

Overall

Beta: 1.46
Market Cap(Mil.): $75.91
Shares Outstanding(Mil.): 47.44
Dividend: --
Yield (%): --

Financials

  ADMP.OQ Industry Sector
P/E (TTM): -- 30.96 35.38
EPS (TTM): -0.96 -- --
ROI: -103.73 12.01 11.72
ROE: -110.00 13.30 16.38

BRIEF-Adamis Pharmaceuticals’ Commercial Partner Launches Symjepi (Epinephrine) In The US

* ADAMIS’ COMMERCIAL PARTNER LAUNCHES SYMJEPI™ (EPINEPHRINE) IN THE US

16 Jan 2019

Swiss stocks - Factors to watch on Dec. 7

ZURICH/BERLIN, Dec 7 The Swiss blue-chip SMI was seen opening 1.2 percent higher at 8,765 points on Friday, according to premarket indications by bank Julius Baer .

07 Dec 2018

Novartis to launch Adamis' EpiPen rival in U.S. next year

Dec 6 Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.

07 Dec 2018

BRIEF-Adamis Pharmaceuticals Provides Update On Symjepi's U.S. Launch

* ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON THE U.S. LAUNCH OF SYMJEPI

06 Dec 2018

Earnings vs. Estimates